SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Allogeneic, Autologous, CAR-T, CD19, TCR

November 16, 2020

Ziopharm’s TCR-T Program at the NCI Continues to Face Delays; MD Anderson Hotspot TCR-T IND Filing on Track for 2021; Q3 2020 Earnings Call Summary

Here is a brief preview of this blast: On Thursday, November 5, Ziopharm held their Q3 2020 earnings call (press release / presentation) highlighting that their TCR-T and RPM CAR-T programs remain on track. Of note, management commented that in Q1 2021 they anticipate filing an IND application for their MD Anderson, library TCR-T program. Below, Celltelligence provides insights on Ziopharm’s TCR-T and CAR-T programs, as well as the potential risk associated with further clinical delays.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.